### ü´Å Pulmonary Medicine: Arteriovenous Malformation on Chest Radiography

#### ‚úÖ True Statements
1. An **arteriovenous malformation (AVM)** may appear on chest radiography as a **smooth, sharply circumscribed, homogeneous nodular lesion**.
2. A **3-cm nodular lesion** at the **base of the right lung** without **hilar or mediastinal lymphadenopathy** is consistent with an **arteriovenous malformation**.
3. **Nodular lung lesions** may be caused by **bronchogenic carcinoma** or **metastatic cancer**, but in a **young nonsmoking patient**, a **congenital or developmental lesion** such as an **arteriovenous malformation** is more likely.
4. **Contrast-enhanced chest computed tomography (CT)** can confirm the diagnosis of an **arteriovenous malformation**.

#### üí¨ Extra
1. Smooth and homogeneous density on radiography helps distinguish AVMs from irregular or spiculated malignant lesions.
2. The absence of lymphadenopathy reduces suspicion for malignant causes.
3. Patient demographics (age ‚â§25 years, nonsmoker) strongly favor congenital lesions rather than malignancy.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #AmbulatoryCare #PatientUnder25 #ChestRadiography #ArteriovenousMalformation #LungLesion

#### üìö Reference
MKSAP 19 Pulmonary and Critical Care Medicine. American College of Physicians.

#### üÜî Question ID
PMVDX24018

#### üïí Last Updated
February 2025

---

#### üñºÔ∏è Supplemental Figures

<figure>
  <img src="Diagnose an arteriovenous malformation on chest radiography.jpg" alt="Chest radiograph showing arteriovenous malformation at base of right lung" />
  <figcaption><strong>Chest Radiograph: Arteriovenous Malformation.</strong> A 3-cm, smooth, sharply circumscribed, homogeneous nodular lesion at the base of the right lung consistent with an AVM.</figcaption>
</figure>

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Lung Tumors, Pulmonary Nodule Evaluation

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. On imaging, **pulmonary nodules** are defined as **small opacities <3 cm** surrounded by normal lung parenchyma, whereas a **focal opacity >3 cm** is considered a **lung mass** and presumed malignant until proved otherwise.
2. **Pulmonary nodules** are frequently detected **incidentally** because of the high use of **chest CT** for other indications.
3. **Lung masses (>3 cm)** should be presumed **malignant until proved otherwise**.
4. When multiple pulmonary nodules are present, **follow-up is determined by the largest lesion**.
5. A **well-demarcated, centrally or fully calcified nodule** usually represents a **previous infectious granuloma** and is considered **benign**.
6. Common infectious causes of **benign granulomatous nodules** include **endemic fungi** (e.g., histoplasmosis) and **mycobacteria** (e.g., tuberculosis, nontuberculous mycobacteria).
7. **Subsolid nodules**, including **pure ground-glass** and **part-solid nodules**, often represent **premalignant adenocarcinoma in situ** and may grow very slowly, with doubling times between **400‚Äì800 days**.
8. **Development or growth of a solid component** in a **subsolid nodule** suggests **malignancy**.
9. **Subsolid nodules** are not reliably characterized by **PET/CT**, and **nonsurgical biopsies** have limited sensitivity.
10. The **Brock model** and similar prediction calculators estimate malignancy risk based on factors such as **age, sex, smoking history, nodule size, lung location, and border morphology**.
11. **Solid nodules >8 mm** with moderate risk should be further characterized with **PET/CT**, with management based on results.
12. **Solid nodules >8 mm** with high risk should be staged with **PET/CT** followed by **definitive management** (e.g., resection, chemotherapy, radiation).

#### üè∑Ô∏è Tags
#PulmonaryNodule #PulmonaryMedicine #Granuloma #AdenocarcinomaInSitu #PETCT #BrockModel

---

#### üóæ Supplemental Tables

<!-- Table 1: Solid Nodules -->
<table>
  <caption><strong>Recommendations for Single Pulmonary Nodule Follow-Up (Fleischner Society)</strong></caption>
  <thead>
    <tr>
      <th>Nodule Size</th>
      <th>Low-Risk Patient</th>
      <th>High-Risk Patient</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><strong>&lt;6 mm</strong></td>
      <td>No follow-up</td>
      <td>Optional CT at 12 months</td>
    </tr>
    <tr>
      <td><strong>6‚Äì8 mm</strong></td>
      <td>CT at 6‚Äì12 months; consider CT at 18‚Äì24 months</td>
      <td>CT at 6‚Äì12 months and at 18‚Äì24 months</td>
    </tr>
    <tr>
      <td><strong>&gt;8 mm</strong></td>
      <td colspan="2">CT at 3 months, PET/CT, or tissue sampling</td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Recommendations for Single Pulmonary Nodule Follow-Up)
1. For **incidentally detected pulmonary nodules <6 mm** in **low-risk patients**, **no follow-up** is required.
2. For **incidentally detected pulmonary nodules <6 mm** in **high-risk patients**, **optional chest CT at 12 months** may be performed.
3. For **6‚Äì8 mm pulmonary nodules** in **low-risk patients**, **chest CT at 6‚Äì12 months** is recommended, with optional **chest CT at 18‚Äì24 months**.
4. For **6‚Äì8 mm pulmonary nodules** in **high-risk patients**, **chest CT at 6‚Äì12 months** and **again at 18‚Äì24 months** is recommended.
5. For **pulmonary nodules >8 mm** in any patient, evaluation should include **chest CT at 3 months, PET/CT, or tissue sampling**.

---

<!-- Table 2: Subsolid Nodules -->
<table>
  <caption><strong>Recommendations for Solitary Subsolid Lung Nodule Follow-Up (Fleischner Society)</strong></caption>
  <thead>
    <tr>
      <th>Imaging Findings</th>
      <th>Size</th>
      <th>Recommended Follow-Up</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pure ground glass</td>
      <td>&lt;6 mm</td>
      <td>No follow-up</td>
    </tr>
    <tr>
      <td>Pure ground glass</td>
      <td>&ge;6 mm</td>
      <td>CT at 6‚Äì12 months to confirm persistence, then CT every 2 years until 5 years</td>
    </tr>
    <tr>
      <td>Part-solid nodule</td>
      <td>&lt;6 mm</td>
      <td>No follow-up</td>
    </tr>
    <tr>
      <td>Part-solid nodule</td>
      <td>&ge;6 mm</td>
      <td>CT at 3‚Äì6 months to confirm persistence; if unchanged and solid component remains &lt;6 mm, annual CT for 5 years</td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Recommendations for Solitary Subsolid Lung Nodule Follow-Up)
1. **Pure ground-glass nodules <6 mm** require **no follow-up**.
2. **Pure ground-glass nodules ‚â•6 mm** require **CT at 6‚Äì12 months to confirm persistence**, followed by **CT every 2 years up to 5 years**.
3. **Part-solid nodules <6 mm** require **no follow-up**.
4. **Part-solid nodules ‚â•6 mm** require **CT at 3‚Äì6 months to confirm persistence**; if unchanged and the solid component remains **<6 mm**, **annual CT for 5 years** is recommended.

#### üè∑Ô∏è Tags
#PulmonaryNodule #GroundGlassNodule #PartSolidNodule #FleischnerSociety #PulmonaryMedicine #AmbulatoryCare

---

#### üñºÔ∏è Supplemental Figures

<figure>
  <img src="Radiographic Evolution of Part-Solid Pulmonary Nodule.jpg" alt="CT images showing part-solid pulmonary nodule evolution over 6 years." />
  <figcaption>
    <strong>Radiographic Evolution of Part-Solid Pulmonary Nodule.</strong>  
    Radiographs show a part-solid, part‚Äìground-glass nodule in the left upper lobe (A); growth in the solid component at 1 year (B); an increase in the ground-glass component at 4 years (C); and further growth of the solid component at 6 years (D). This slow growth pattern is characteristic of part-solid nodules progressing from adenocarcinoma in situ to invasive adenocarcinoma.  
    Reprinted with permission from the Radiological Society of North America. MacMahon H, Naidich DP, Goo JM, et al. *Radiology*. 2017;284:228‚Äì43. PMID: 28240562
  </figcaption>
</figure>